<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20151107024909N12</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-30</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of dexmedetomidine with propofol in maintaining adequate depth of anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of dexmedetomidine as a main anastasia drug with propofol on maintain sufficient depth of anesthesia in patients undergoing elective laparotomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65952</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly divided into two groups. The randomization tool will be a random sequence generation software called SAS. In addition to simple randomization, these random sequence generation software are capable of generating random sequence by block method. Block randomization method will be used for randomization. Block randomization is for the purpose of making sure that exactly equal number of participants enter the study groups. The advantages of block randomization are that the balance of the number of participants in each group is guaranteed. For this purpose, 6 blocks will be formed and in each block, 3 people from intervention group and 3 people in control group 3 will be placed. A total of 5 blocks will be considered to reach the sample size. The blocks contain numbers,  odd numbers represent the intervention group and even numbers represent the control group. Their order  will be determined by the software initially.
Random allocation concealment will be done using opaque envelopes sealed with a random sequence, in this method, each of the random sequences created is recorded on a card and the cards are placed inside the envelopes in order. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the letter envelopes are glued and placed in a box, respectively. the door
At the beginning of the registration of participants, based on the order of entry of eligible participants into the study, one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed, Blinding description: The surgeon and the patients will be blinded and unaware of the type of anesthesia. Similar serums were used for concealment, without drug name labels and only with a code. Patients will be aware that they will be randomly assigned to one of the two treatment groups but will not know which treatment will be provided in that group. The surgeon also knows that two different methods will anesthetize the patients, but he will not know which method will be used for each patient. The person in charge of data collection, the analyst, and the outcome evaluator will collect and analyze the data based on groups 1 and 2 and will not know the type of treatment provided in the groups and will be kept blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Induction included midazolam 0.03 mg/kg (Manufacturing factory: Abu Rayhan), fentanyl 2 mg/kg (manufacturer: Norman SA), propofol 1-2 mg/kg (manufacturer: Bran B), cis-atracurium 0.2 mg/kg. kg (Manufacturing factory: Behin Tamin Roza Mod Co.) After reaching the necessary conditions for intubation, the patient is intubated with a suitable size tube. During this time, the dexmedetomidine infusion continues. In order to administer anesthesia during the procedure, the infusion of dexmedetomidine (manufacturer: Exir) continues at a rate of 1 mcg/kg/hr, and the patient receives 5 mg of morphine intravenously, and the infusion of cis-atracurium is started at the rate of 2 mcg/kg/min. If the depth of anesthesia increases more than 50, the amount of dexmedetocidin 0.25% is added and it can be added up to ten times the initial sedation dose to maintain the level of sedation at 40-50. If the depth of anesthesia decreases from 40 in this group, the dose of dexmedetomidine will be reduced until the depth of anesthesia reaches an acceptable level, and if there is no response to increasing the dose of propofol or complications, isoflurane gas (manufacturer: Piramal) will be used in the amount of 0.5%. As long as the depth of anesthesia can be maintained as necessary, the concentration of inhalation gas is increased. Intervention 2: Control group: Induction included midazolam 0.03 mg/kg (Manufacturing factory: Abu Rayhan), fentanyl 2 mg/kg (manufacturer: Norman SA), propofol 1-2 mg/kg (manufacturer: Bran B), cis-atracurium 0.2 mg/kg. kg (Manufacturing factory: Behin Tamin Roza Mod Co.) After reaching the necessary conditions for intubation, the patient is intubated with a suitable size tube. Normal saline infusion continues during this time. To administer anesthesia during the procedure, propofol infusion is started at a dose of 50-100 mcg/kg/min (Manufacturing factory: Shafa Farmed). Patients receive 5 mg of intravenous morphine and the infusion of Cis-atracurium starts with a dose of 2 mcg/kg/min. To keep the depth of anesthesia constant between 40-50, if the depth of anesthesia increases by 20%, the infusion of propofol will be increased. And if the depth of anesthesia falls below 40, the amount of propofol will be reduced by 20% and this will continue until the depth of anesthesia can be kept between 40 and 50 and the maximum dose of propofol (200 ug/kg) reached, and in case of failure to respond to propofol dose increase or side effects, 0.5% isoflurane gas (manufacturer: Piramal) will be used until the depth of anesthesia can be maintained at the required level, the inhalation gas concentration will be increased.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After completing the work and consulting with all the writers and executive agents, I will be decided.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Faranak Rokhtabnak</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Firouzgar hospital. Vali Asr Sq. Beh Afarin Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1593747811</zip>
        <telephone>+98 21 6640 6761</telephone>
        <email>rolhtabnak.f@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Faranak Rokhtabnak</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Firouzgar hospital. Vali Asr Sq. Beh Afarin Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1593747811</zip>
        <telephone>+98 21 6640 6761</telephone>
        <email>rolhtabnak.f@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 20 years
Patients who are candidates for laparotomy surgery
Surgery with a time of more than 3 hours under general anesthesia</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients over 60 years
Emergency surgery
Contraindications to the use of dexmedetomidine
Pregnancy or breastfeeding
Drug addiction
Uncontrolled blood pressure
Body mass index above 30</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y48.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anaesthetic, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Induction included midazolam 0.03 mg/kg (Manufacturing factory: Abu Rayhan), fentanyl 2 mg/kg (manufacturer: Norman SA), propofol 1-2 mg/kg (manufacturer: Bran B), cis-atracurium 0.2 mg/kg. kg (Manufacturing factory: Behin Tamin Roza Mod Co.) After reaching the necessary conditions for intubation, the patient is intubated with a suitable size tube. During this time, the dexmedetomidine infusion continues. In order to administer anesthesia during the procedure, the infusion of dexmedetomidine (manufacturer: Exir) continues at a rate of 1 mcg/kg/hr, and the patient receives 5 mg of morphine intravenously, and the infusion of cis-atracurium is started at the rate of 2 mcg/kg/min. If the depth of anesthesia increases more than 50, the amount of dexmedetocidin 0.25% is added and it can be added up to ten times the initial sedation dose to maintain the level of sedation at 40-50. If the depth of anesthesia decreases from 40 in this group, the dose of dexmedetomidine will be reduced until the depth of anesthesia reaches an acceptable level, and if there is no response to increasing the dose of propofol or complications, isoflurane gas (manufacturer: Piramal) will be used in the amount of 0.5%. As long as the depth of anesthesia can be maintained as necessary, the concentration of inhalation gas is increased.</i_keyword>
      <i_keyword>Control group: Induction included midazolam 0.03 mg/kg (Manufacturing factory: Abu Rayhan), fentanyl 2 mg/kg (manufacturer: Norman SA), propofol 1-2 mg/kg (manufacturer: Bran B), cis-atracurium 0.2 mg/kg. kg (Manufacturing factory: Behin Tamin Roza Mod Co.) After reaching the necessary conditions for intubation, the patient is intubated with a suitable size tube. Normal saline infusion continues during this time. To administer anesthesia during the procedure, propofol infusion is started at a dose of 50-100 mcg/kg/min (Manufacturing factory: Shafa Farmed). Patients receive 5 mg of intravenous morphine and the infusion of Cis-atracurium starts with a dose of 2 mcg/kg/min. To keep the depth of anesthesia constant between 40-50, if the depth of anesthesia increases by 20%, the infusion of propofol will be increased. And if the depth of anesthesia falls below 40, the amount of propofol will be reduced by 20% and this will continue until the depth of anesthesia can be kept between 40 and 50 and the maximum dose of propofol (200 ug/kg) reached, and in case of failure to respond to propofol dose increase or side effects, 0.5% isoflurane gas (manufacturer: Piramal) will be used until the depth of anesthesia can be maintained at the required level, the inhalation gas concentration will be increased.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depth of anesthesia. Timepoint: At the beginning and during surgery. Method of measurement: Anesthesia depth monitoring device.</prim_outcome>
      <prim_outcome>Pain level of patients. Timepoint: From the beginning of recovery every 15 minutes up to three times. Method of measurement: Visual analog scale.</prim_outcome>
      <prim_outcome>Agitation score. Timepoint: From the beginning of recovery every 15 minutes up to three times. Method of measurement: Based on the information in the patient's file.</prim_outcome>
      <prim_outcome>Sedition score. Timepoint: From the beginning of recovery every 15 minutes up to three times. Method of measurement: Based on the information in the patient's file.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-23</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
